Belvedere Trading
KPTI icon

Belvedere Trading’s Karyopharm Therapeutics KPTI Stock Holding History

Belvedere Trading’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,563
Closed -$89.1K – 967
2025
Q3 		$95.2K Buy
+14,563
New +$78.4K ﹤0.01% 596
2022
Q1 		– Sell
-358
Closed -$44K – 546
2021
Q4 		$44K Buy
+358
New +$35.7K ﹤0.01% 368

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Belvedere Trading's KPTI Position: Q4 2025 in Review

Belvedere Trading sold out of Karyopharm Therapeutics (KPTI) in Q4 2025, closing a stake of 14,563 shares — an estimated $89.1K sold.

Belvedere Trading first reported a position in KPTI in Q4 2021 and held it in 2 quarters. The position peaked at $95.2K in Q3 2025. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • Belvedere Trading reported no remaining Karyopharm Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Belvedere Trading sold 14,563 Karyopharm Therapeutics shares in Q4 2025, an estimated $89.1K.
  • Belvedere Trading first reported a position in Karyopharm Therapeutics in Q4 2021 and held it in 2 quarters.
  • Belvedere Trading's Karyopharm Therapeutics position peaked at $95.2K in Q3 2025.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on Belvedere Trading's 13F filing for Q4 2025, filed 10 Feb 2026.